Olfactory dysfunction but not COVID-19 severity predicts severity of cognitive sequelae following SARS-CoV-2 infection in Amerindian older adults

• Autores: Gonzalez Aleman, Gabriela; Zamponi, Hernan P.; Juarez Aguaysol, Leonardo; Kukoc, Gabriela; Domínguez, María Eugenia; Pini, Belén; Padilla, Eduardo G.; Calvó, María; Molina Rangeo, Silvia Beatriz; Guerrero, Gonzalo; Figueredo Aguiar, Mariana; Fumagalli, Emiliano; Vaca, Fabiana; Yécora, Agustín; Brugha, Traolach S.; Seshadri, Sudha; Snyder, Heather M.; Erausquin, Gabriel A. de
• Año de publicación: 2022
• Idioma: inglés
• Tipo de recurso: artículo
• Fuente: Alzheimers Dement Vol.18, No.7, 2022
• Materia: COVID-19; ADULTOS MAYORES; ENFERMEDAD DE ALZHEIMER; DISFUNCION OLFATORIA
• Institución: Pontificia Universidad Católica Argentina

Fil: Gonzalez Aleman, Gabriela. Pontificia Universidad Catolica Argentina; Argentina
Fil: Zamponi, Hernan P. Miinisterio de Salud de Jujuy; Argentina
Fil: Juarez Aguaysol, Leonardo. Miinisterio de Salud de Jujuy; Argentina
Fil: Kukoc, Gabriela. Miinisterio de Salud, San Salvador de Jujuy; Argentina
Fil: Domínguez, María Eugenia. Ministerio de Salud de Jujuy; Argentina
Fil: Pini, Belén. Ministerio de Salud de Jujuy; Argentina
Fil: Padilla, Eduardo G. Fundación de Lucha contra los Trastornos Neurológicos y Psiquiátricos en Minorías; Argentina
Fil: Calvó, María. Fundación de lucha contra los trastornos neurológicos y psiquiátricos en minorías; Argentina
Fil: Molina Rangeo, Silvia Beatriz. Fundación de lucha contra los trastornos neurológicos y psiquiátricos en minorías; Argentina
Fil: Guerrero, Gonzalo. Fundación de lucha contra los trastornos neurológicos y psiquiátricos en minorías; Argentina
Fil: Figueredo Aguiar, Mariana. Fundación de lucha contra los trastornos neurológicos y psiquiátricos en minorías; Argentina
Fil: Fumagalli, Emiliano. 6Universidad Nacional de Jujuy; Argentina
Fil: Vaca, Fabiana. Miinisterio de Salud de Jujuy; Argentina
Fil: Yécora, Agustín. Ministerio de Salud de Jujuy; Argentina
Fil: Brugha, Traolach S. University of Leicester; Reino Unido
Fil: Seshadri, Sudha. University of Texas Health Science Center. Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases; Estados Unidos
Fil: Snyder, Heather M. Alzheimer’s Association; Estados Unidos
Fil: Erausquin, Gabriel A. de. University of Texas Health Science Center. Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases; Estados Unidos
Abstract Background: COVID-19 has affected more than 380 million people. Infections may result in long term sequelae, including neuropsychiatric symptoms. In older adults COVID-19 sequelae resemble early Alzheimer’s disease, and may share risk factors and blood biomarkers with it. The Alzheimer’s Association Consortium on Chronic Neuropsychiatric Sequelae of SARS-CoV-2 infection (CNS SC2) established harmonized definitions, ascertainment and assessment methodologies to evaluate and longitudinally follow up cohorts of older adults with exposure to COVID-19. We present one year data in a prospective cohort from Argentina. Method: Participants (n = 766) are older adults (≥60 years) recruited from the provincial health registry containing all SARS-CoV-2 testing data. We randomly invite older adults stratified by PCR COVID-19 testing status regardless of symptom severity, between 3 and 6 months after recovery. Assessment includes interview with the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) and Clinical Dementia Rating scale (CDR); neurocognitive assessment; emotional reactivity scale; and neurological assessment including semiquantitative olfactory function test, motor function, coordination and gait. Result: We assessed 88.4% infected participants and 11.6 % controls. Education is 10.36 ± 5.6 years and age is 66.9 ± 6.14 years. Level of care during COVID-19 is described in Figure 1. Normalized cognitive Z-scores categorize the cohort in 3 groups with decreased performance compared to normal cognition: memory only impairment (Single-domain,11.7%); impairment in attention+executive function without memory impairment (Two-domain, 8.3%); and multiple domain impairment (Multiple domain,11.6%). Logistic regression showed that severity of anosmia, but not clinical status, significantly predicts cognitive impairment. No controls had olfactory dysfunction. Cognitive impairment is defined as Z-scores below (- 2) (Table 1). Clinical assessment with SCAN revealed functional memory impairment in two thirds of infected patients (CDR ≥ 1), which was severe in half of them. Phone-based follow up at 1 year revealed high adherence (4 participants declined). Five were deceased at follow up. Rates of re-infection (between 10 and 23%) were not affected by the vaccination schedule (Table 2). Conclusion: The longitudinal cohort had very high adherence. Persistent cognitive and functional impairment after SARS-CoV-2 infection is predicted by persistent anosmia but not by the severity of the initial COVID-19 disease.